Glooko has secured US Food and Drug Administration (FDA) clearance for EndoTool IV Cloud, priming the cloud-based insulin dosing platform for commercialisation across hospital settings.

Endotool is a computer software system that supports individualised insulin dosing for critically ill hospitalised patients who require intravenous insulin therapy. Glooko inherited EndoTool, the first iteration of which secured FDA clearance in 2006, following its acquisition of Monarch Medical Technologies in September 2025. The terms of the acquisition were not publicly disclosed.

The cloud-based model is designed to reduce the need of on premise infrastructure and supports a more scalable approach for hospitals adopting or expanding the use of EndoTool IV, Glooko stated.